FC
ALLO icon

FORA Capital’s Allogene Therapeutics ALLO Stock Holding History

FORA Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,097
Closed -$107K – 361
2021
Q2 		$107K Buy
+4,097
New +$117K 0.02% 580
2021
Q1 		– Sell
-4,032
Closed -$102K – 754
2020
Q4 		$102K Buy
+4,032
New +$131K 0.02% 662
2020
Q3 		– Sell
-2,947
Closed -$126K – 638
2020
Q2 		$126K Buy
+2,947
New +$107K 0.04% 438

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FORA Capital's ALLO Position: Q3 2021 in Review

FORA Capital sold out of Allogene Therapeutics (ALLO) in Q3 2021, closing a stake of 4,097 shares — an estimated $107K sold.

FORA Capital first reported a position in ALLO in Q2 2020 and held it in 3 quarters. The position peaked at $126K in Q2 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q3 2021.

  • FORA Capital reported no remaining Allogene Therapeutics position as of Q3 2021 after selling out during the quarter.
  • FORA Capital sold 4,097 Allogene Therapeutics shares in Q3 2021, an estimated $107K.
  • FORA Capital first reported a position in Allogene Therapeutics in Q2 2020 and held it in 3 quarters.
  • FORA Capital's Allogene Therapeutics position peaked at $126K in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.